HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dario Baratti Selected Research

Pseudomyxoma Peritonei

1/2021Phase II randomized study on tissue distribution and pharmacokinetics of cisplatin according to different levels of intra-abdominal pressure (IAP) during HIPEC (NCT02949791).
1/2021The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.
1/2019Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei.
4/2018Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series.
2/2018Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
1/2016GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study.
7/2013Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
7/2012Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
2/2009Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
2/2008Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Dario Baratti Research Topics

Disease

24Mesothelioma
10/2022 - 07/2003
24Peritoneal Neoplasms
12/2021 - 03/2006
19Neoplasms (Cancer)
10/2022 - 06/2002
18Neoplasm Metastasis (Metastasis)
08/2022 - 09/2013
13Pseudomyxoma Peritonei
01/2021 - 04/2004
11Colorectal Neoplasms (Colorectal Cancer)
01/2021 - 09/2008
6Residual Neoplasm
01/2021 - 08/2007
5Carcinoma (Carcinomatosis)
12/2021 - 02/2006
4Sarcoma (Soft Tissue Sarcoma)
11/2017 - 09/2008
3Peritoneal Diseases
12/2021 - 04/2018
3Ovarian Neoplasms (Ovarian Cancer)
05/2021 - 06/2014
2Lymphatic Metastasis
01/2021 - 12/2009
2Neoplasms, Cystic, Mucinous, and Serous
01/2021 - 04/2018
2Disease Progression
04/2016 - 01/2010
2Ovarian Epithelial Carcinoma
08/2011 - 09/2008
1Stomach Neoplasms (Stomach Cancer)
12/2021
1Appendiceal Neoplasms (Appendix Cancer)
01/2021
1Rupture
04/2018
1Vomiting
04/2015
1Nausea
04/2015
1Pruritus (Itching)
04/2015
1Respiratory Insufficiency (Respiratory Failure)
04/2015
1Pain (Aches)
04/2015
1Colonic Neoplasms (Colon Cancer)
12/2014
1Retroperitoneal liposarcoma
12/2010
1Leiomyosarcoma
12/2010
1Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor)
12/2010
1HIV Infections (HIV Infection)
03/2010
1Fistula
01/2009
1Pancreatic Fistula (Pancreatic Fistulas)
12/2007
1Hyperamylasemia
12/2007
1Infections
09/2007
1Necrosis
11/2005
1Rare Diseases (Rare Disease)
04/2004
1Adenocarcinoma
06/2002

Drug/Important Bio-Agent (IBA)

5Biomarkers (Surrogate Marker)IBA
10/2022 - 11/2005
4Cisplatin (Platino)FDA LinkGeneric
01/2021 - 02/2008
4Mitomycin (Mitomycin-C)FDA LinkGeneric
01/2020 - 02/2009
4Biological ProductsIBA
06/2011 - 02/2008
3MucinsIBA
01/2021 - 04/2004
2Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2017 - 12/2014
2Tumor Biomarkers (Tumor Markers)IBA
07/2013 - 08/2007
2Pharmaceutical PreparationsIBA
10/2010 - 02/2006
1MicroRNAs (MicroRNA)IBA
10/2022
1Capecitabine (Xeloda)FDA Link
01/2019
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2019
1Antigen-Antibody Complex (Immune Complex)IBA
01/2018
1MesothelinIBA
01/2018
1OsteopontinIBA
01/2018
1Irinotecan (Camptosar)FDA LinkGeneric
01/2017
1Serum AlbuminIBA
12/2015
1Proteins (Proteins, Gene)FDA Link
12/2015
1Paclitaxel (Taxol)FDA LinkGeneric
06/2014
1Carboplatin (JM8)FDA LinkGeneric
06/2014
1Doxorubicin (Adriamycin)FDA LinkGeneric
10/2013
16-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA
05/2012
1Imatinib Mesylate (Gleevec)FDA Link
12/2010
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
10/2010
1Phosphotransferases (Kinase)IBA
10/2010
1tyrosine receptor (receptor, tyrosine)IBA
10/2010
1Platelet-Derived Growth Factor beta Receptor (Receptor, Platelet Derived Growth Factor beta)IBA
10/2010
1Telomerase (Telomerase Reverse Transcriptase)IBA
07/2008
1SurvivinIBA
01/2007
11-methyl-1-piperidinomethane sulfonateIBA
01/2007
1Matrix Metalloproteinase 9 (Gelatinase B)IBA
02/2006
1ErbB Receptors (EGF Receptor)IBA
02/2006
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
02/2006
1Calbindin 2IBA
11/2005
1Leucovorin (Folinic Acid)FDA Link
06/2002
1Fluorouracil (Carac)FDA LinkGeneric
06/2002
1doxifluridineIBA
06/2002

Therapy/Procedure

56Hyperthermic Intraperitoneal Chemotherapy
08/2022 - 11/2006
52Cytoreduction Surgical Procedures
08/2022 - 07/2003
22Drug Therapy (Chemotherapy)
12/2021 - 06/2002
4Therapeutics
11/2019 - 09/2008
3Laparotomy
12/2021 - 03/2014
2Contraindications
03/2018 - 01/2018
2Molecular Targeted Therapy
12/2010 - 01/2010
1Gastrectomy
12/2021
1Appendectomy
12/2021
1Gynecologic Surgical Procedures (Gynecologic Surgery)
05/2021
1Operative Time
10/2018
1Hysterectomy
04/2018
1Ovariectomy (Oophorectomy)
04/2018
1Epidural Analgesia
04/2015
1Splenectomy
12/2007
1Surgical Amputation (Amputations)
12/2007
1Induction Chemotherapy
07/2003
1Intravenous Infusions
06/2002
1Radiotherapy
06/2002